Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Stockholders to Inquire about Securities Investigation

NodeGuardian · 2026-03-30T17:01:48+00:00

Bronstein, Gewirtz & Grossman, LLC is exploring potential claims for PROCEPT BioRobotics stockholders after the company reported a significant adjusted EBITDA loss and reduced 2026 revenue guidance, leading to a decline in stock price.

NodeGuardian

2026-03-30 17:01:48

Abstract generation in progress

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of PROCEPT BioRobotics Corporation (PRCT) stockholders following a disclosed larger-than-expected adjusted EBITDA loss and a cut in full-year 2026 revenue guidance. The firm encourages investors who purchased PROCEPT securities to inquire about this ongoing securities investigation. This investigation comes after PROCEPT’s stock price dropped due to changes in its discounting practices affecting consumable revenue.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes